422 results about "Liver damage" patented technology

The invention relates to the technical field of hepatitis diagnosis and treatment management, and discloses a block chain-based hepatitis patient full-period management method. The method comprises the following steps: creating a patient identity chain in a block chain network, and storing patient registration data and initial diagnosis information; full-cycle diagnosis and treatment data of a patient are obtained and divided into clinical examination, iconography, medication records and life sign monitoring data. Performing multi-dimensional cleaning on the clinical examination data to generate a standardized data set; inputting the iconography data into a pre-trained hepatitis feature extraction model, and outputting a liver injury feature set; verifying the integrity of the medication record, and generating a non-tampering medication time sequence chain; comparing the life sign monitoring data with preset health reference parameters to generate a sign deviation coefficient set; according to the method, data safety and traceability are guaranteed through the block chain, diagnosis and treatment data quality is improved through multi-dimensional data processing, patient privacy is protected, and reliable support is provided for full-period management of hepatitis patients.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The application discloses a Weizmannia coagulans with fat-reducing and weight-reducing functions, and belongs to the technical field of microorganisms. The Weizmannia coagulans screened by the application can inhibit the content and activity of fat synthesis enzyme on the basis of reducing blood fat and weight, can relieve liver damage caused by high-fat diet, has excellent acid tolerance, bile salt tolerance and high fat hydrolysis capacity, and is a multifunctional Weizmannia coagulans, and has a wide application prospect in the preparation of fat-reducing, weight-reducing and weight-losing products.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention belongs to the technical field of medicines, and particularly relates to a plant lactobacillus for relieving acute alcoholic liver injury as well as a metagen and application of the plant lactobacillus. The strain of the plant lactobacillus L5-13 is preserved in the China Center for Type Culture Collection on August 18, 2025, and the preservation number of the strain is CCTCC NO: M 20251835. The strain and the metagen thereof can significantly improve pathological symptoms of mice with acute alcoholic liver injury, including: reducing the levels of ALT, AST, TC, TG and LDL-C in serum of the mice with acute alcoholic liver injury, and increasing the level of HDL-C; the abnormal blood lipid level of the mouse caused by acute alcohol is regulated; the activity of antioxidant enzymes in the liver is improved, and the lipid peroxidation level is reduced; the ethanol dehydrogenase activity of the liver is improved, and the ethanol metabolism capability is enhanced. Therefore, the strain and the metagen thereof have wide application prospects in prevention or treatment of acute alcoholic liver injury.

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention discloses a preparation method of 20 (E)-ginsenoside F4 and application of the 20 (E)-ginsenoside F4 in preparation of anti-liver injury medicines, and relates to the technical field of biological medicines. The rare ginsenoside 20 (E)-ginsenoside F4 is prepared and purified from ginsenoside Re through an acid catalytic conversion method, and the rare ginsenoside 20 (E)-ginsenoside F4 shows remarkable advantages and wide prospects in research and development of liver protection drugs. The monomer has strong liver protection activity, complies with the development trend of monomeric compound preparations, and provides efficient active ingredients for liver protection drugs. The 20 (E)-ginsenoside F4 with efficient activity, excellent safety and environment-friendly preparation characteristics can be widely applied to preparation of liver protection drugs or pharmaceutical compositions, especially drugs or pharmaceutical compositions for treating liver injury caused by chemotherapeutic drugs.

The invention discloses a preparation method of a liver protection medicine composition containing dihydromyricetin, and relates to the technical field of medicine preparation.According to the method, dihydromyricetin, puerarin, pueraria flower extract, corn oligopeptide, pyrroloquinoline quinone disodium salt, curcumin and ganoderan are used as raw materials; dihydromyricetin and puerarin are stirred, homogenized and dried in a mixed solvent to prepare the liver protection medicine composition, wherein the mass ratio of dihydromyricetin to puerarin is 1: (0.5-2). A multi-target liver protection system is constructed through cooperation of multiple components, the problems that a traditional liver protection medicine is poor in component solubility, easy to degrade in activity and weak in synergistic effect are solved, the bioavailability and stability of the product are improved, the process is simple and controllable, the preparation method is suitable for industrial production and can be prepared into oral preparations such as tablets and oral liquid, and the preparation method is suitable for industrial production. The composition is suitable for protection of alcoholic and chemical liver injury.

The invention discloses a genetically engineered probiotic composition for expressing ADH (adenosine dihydrogenase) and ALDH (aldehyde dehydrogenase) and application of the genetically engineered probiotic composition in hangover alleviating and liver protection. The genetically engineered probiotic composition (such as EcN.1917-ADH and EcN.1917-ALDH) is constructed by introducing genes of alcohol dehydrogenase (ADH, NCBI (National Center for Biotechnology Information) Gene ID: 855349) and acetaldehyde dehydrogenase (ALDH, NCBI Gene ID: 855206) of saccharomyces cerevisiae into probiotics (such as escherichia coli). The engineering bacterium shows remarkable ethanol, acetaldehyde and endurance capacity in an in-vitro experiment, and the ethanol degradation rate is remarkably higher than that of a wild type strain; a mouse drunkenness model verifies that drunkenness and death caused by drinking can be reduced through pretreatment, drunkenness tolerance time is remarkably prolonged, and movement coordination disorder caused by alcohol can be improved. The strain can effectively promote alcohol metabolism and relieve alcoholic liver injury, and a new candidate strain is provided for development of a hangover-alleviating and liver-protecting viable bacterial preparation.

The invention provides nano selenium-rich yellow wine as well as a preparation method and application thereof, and belongs to the technical field of biology. According to the method, the selenium-rich yellow wine is subjected to ohmic heating to 50-85 DEG C, heat preservation is conducted for 1-30 min, efficient sterilization can be achieved, interaction between organic selenium in a yellow wine system and other components contained in the yellow wine can be induced, and uniform nano-selenium particles with the size being 50-100 nm are formed through self-assembly under the synergistic effect of an electric field and a thermal field. According to the in-situ generated nano-selenium particles, the physical stability and chemical stability of the selenium element in a complex system of the yellow wine are remarkably improved, precipitation and biological activity attenuation in the storage period are effectively prevented, and damage of alcohol in the yellow wine to the liver is effectively reduced. The nano selenium-enriched yellow wine prepared by the method has lower alcoholic liver injury effect and is safer to human bodies.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention discloses a cane molasses extract with a blood sugar reducing effect as well as a preparation method and application thereof, and belongs to the field of functional foods. According to the invention, cane molasses is subjected to dissolution, centrifugation, ultrafiltration impurity removal, desalination and nanofiltration concentration, and is mixed with calcium chloride, so that the cane molasses extract with the effect of reducing blood sugar is prepared. Experimental results prove that the cane molasses extract prepared by the invention has the characteristics of low glycemic index (GI), carbohydrate digestive enzyme inhibition, high temperature resistance, long-term storage resistance and the like, can also effectively repair pancreas and liver injury and regulate intestinal flora, and has a comprehensive hypoglycemic effect. The food with low glycemic index is prepared on the basis of the high sucrose carrier for the first time, and the food has sweet taste and the function of reducing blood sugar. The invention provides a new raw material scheme for the preparation of dietary supplement food and hypoglycemic drugs for hyperglycemia people, and has prominent practical application value and wide application prospect.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention discloses an application of costunolide in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is found that costunolide can activate an Nrf2-ARE signal channel of a body, liver cell lipid metabolism abnormality is effectively improved from the molecular level, and meanwhile the pathological influence of oxidative damage on liver tissue is remarkably relieved. Experimental data show that the compound has a remarkable intervention effect on NAFLD, a scientific basis is provided for development of a novel liver disease treatment agent due to the unique dual regulation and control mechanism of the compound, particularly, the compound shows an important development prospect in the field of clinical intervention of metabolism-related liver injury, and an innovative solution is provided for NAFLD lacking a special-effect therapy at present.

The invention discloses a preparation method of crocodile liver peptide for improving liver injury, and relates to the technical field of bioactive peptide extraction, and the preparation method comprises the following steps: crocodile liver pretreatment: cutting fresh crocodile liver into blocks, mixing with deionized water, homogenizing, and adding a zirconium phosphate molecular sieve to obtain crocodile liver homogenate; enzymatic hydrolysis reaction: adjusting the pH value of the homogenate, and adding a compound enzyme preparation for enzymatic hydrolysis; carrying out enzyme deactivation treatment, namely heating, cooling, centrifuging and taking supernate; performing ultrafiltration separation, namely filtering the supernate through an ultrafiltration membrane, and collecting a small molecule peptide solution; purifying and refining: purifying through sephadex column chromatography, and freeze-drying to obtain a crocodile liver peptide product; a double-particle-size zirconium phosphate molecular sieve is constructed to cooperate with a compound enzyme preparation for enzymolysis, electron transfer is enhanced by combining phosphorylation modification, the defects of metal inhibition enzyme activity, insufficient concealed peptide fragment cutting and oxidative damage are overcome, meanwhile, the application of the crocodile liver peptide in the aspect of improving the liver function is researched, and the crocodile liver peptide has a good application prospect. And a new choice is provided for prevention and treatment of liver diseases and liver health care.

The invention provides a strain of Lactobacillus Hilgardii and application thereof, the Lactobacillus Hilgardii is named as Lentibacillus Hilgardii JNLH005, and has been preserved in the Guangdong Microbial Culture Collection Center on November 8, 2024, and the preservation address is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou City, Guangdong Province; the preservation number of the strain is GDMCC No: 65447. Researches show that the Lactobacillus higardsonii has new performance superior to that of the same strain, and the strain and a fermentation product thereof have outstanding performance on dispelling the effects of alcohol, relieving hangover symptoms or preventing / treating digestive system inflammations such as gastrointestinal tract and liver injury caused by alcohol, are efficient in dispelling the effects of alcohol and have no toxic or side effects. The method can be applied to preparation of related medicines, foods or health-care foods.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The invention discloses a composition for enhancing cold resistance based on pyroptosis regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method of the composition for enhancing cold resistance based on pyroptosis regulation comprises the following steps: S1, respectively preparing an angelica sinensis aqueous extract and an astragalus membranaceus aqueous extract; and S2, mixing the angelica sinensis aqueous extract and the astragalus membranaceus aqueous extract according to the mass ratio of 1: (4-20) to obtain the composition for enhancing cold resistance based on pyroptosis regulation. The invention further provides a composition obtained based on the preparation method, a preparation and application. The composition provided by the invention can significantly prolong the survival time of acute cold exposure mice; the core body temperature of an acute cold exposure mouse is obviously improved, liver injury is relieved, and liver tissue cell pyroptosis pathway protein expression is regulated.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with an effect of preventing and treating alcoholic liver injury as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: radix puerariae, turmeric, ginseng, hovenia dulcis thunb, white hyacinth bean, raw oyster shell, poria cocos, raw hawthorn, biond magnolia flower, juncus effuses and albizia flower. The traditional Chinese medicine composition has the effects of soothing liver and harmonizing stomach, dispelling alcohol effect and enlivening spleen, and reinforcing qi and nourishing blood. Experimental results show that the traditional Chinese medicine composition has a good treatment effect on acute alcoholic liver injury and chronic alcoholic fatty liver, and can effectively improve the symptoms of chest rib swelling pain, reduced appetite, anorexia, abdominal distension, hiccup, belching, borborygmus and qi and loose stool caused by liver-stomach disharmony and spleen deficiency and dampness of alcoholic liver injury patients; therefore, the method has good development and utilization prospects.

The invention provides a mulberry phellinus linteus strain SH08, mulberry phellinus linteus polysaccharide as well as a preparation method and application of the mulberry phellinus linteus polysaccharide, and belongs to the technical field of biological medicines and functional foods. The mulberry phellinus igniarius strain SH08 provided by the invention is preserved in the China Center for Type Culture Collection on October 11, 2025, the preservation address is No. 299, eight road, Wuchang District, Wuhan City, Hubei Province, the strain preservation number is CCTCC NO: M20252203, and the mulberry phellinus igniarius strain SH08 is named as SanghuangAKSQSH01. The invention also provides a method for preparing high-purity mulberry phellinus linteus polysaccharide (SHP-PS) from sporocarp of the strain, and structural characterization of the polysaccharide. Experiments prove that the SHP-PS can effectively improve non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, and the mechanism of the SHP-PS is closely related to blood fat regulation, liver injury and inflammation reduction, intestinal barrier repair, intestinal flora structure regulation and short-chain fatty acid generation promotion. The invention provides high-quality raw materials and a clear technical scheme for developing novel medicines or functional foods for preventing and treating NAFLD, and has important application value.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention belongs to the field of biosensing and fluorescence imaging, and particularly relates to a fluorescent probe compound and application thereof. The probe compound is a compound as shown in a formula I or a compound as shown in a formula II, or a pharmaceutically acceptable salt thereof; the structures of the compound in the formula I and the compound in the formula II are shown in the specification, and the definition of each group is shown in any embodiment of the invention. The fluorescent probe compound shows rapid and high reactivity to oxidizing free radicals, the generated fluorescent compound is high in fluorescence intensity and good in stability, and early diagnosis can be carried out on ferroptosis-related disease models such as oxygen-glucose deprivation / reperfusion and drug liver injury on living cell or living body levels and the like. I II

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The invention discloses an anti-drunkenness composition and application thereof. The invention provides an application of a composition in preparation of an anti-drunkenness product, the composition contains edible plasma powder, xylitol, fructo-oligosaccharide, microcrystalline cellulose, mogroside and magnesium stearate, and the edible plasma powder contains immune globulin IgG. The TZK provided by the invention has obvious regulation and improvement effects on sleep behaviors, serum indexes and gastrointestinal injury after acute drinking. The oxidative stress state after long-term large-dose chronic drinking is effectively adjusted, so that the oxidative stress injury index malondialdehyde (MDA) gradually returns to the normal level; according to the present invention, the activity of the liver injury markers such as alanine transaminase (ALT) and aspartate transaminase (AST) is reduced, the liver protection effect is provided, and the gastric mucosa structure repair is promoted by increasing the gastric mucosa prostaglandin content and reducing the local MDA level;

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.